- Trial phase
- Phase 3 (recruiting)
- Time to market
- Phase 3 enrollment began September 2026. With primary completion estimated for June 2029 and regulatory filing thereafter, potential FDA approval for ET is at least 3-4 years away if Phase 3 succeeds. The MF registrational program is still in planning.
- Why 4/10
- No hard dated binary catalyst exists within the next ~12 months. The Phase 3 EXCALIBUR-ET2 trial began enrollment in September 2026 and its primary completion is estimated for June 2029. INCA033989 is one of several pipeline assets at Incyte, a diversified biotech with ~$23.6B market cap and multiple approved commercial products (Jakafi, Opzelura, Monjuvi). A breakthrough designation is not a binary catalyst.
INCA033989 has no imminent binary catalyst. The Phase 3 EXCALIBUR-ET2 trial started enrollment in September 2026 with primary completion estimated for mid-2029, and the registrational program for myelofibrosis remains in planning. Near-term share-price moves for INCY will be driven by commercial execution on Jakafi, Opzelura, and other pipeline readouts (povorcitinib, latarcibart) rather than INCA033989-specific news.
Price Chart
Executive Summary
INCA033989 is a first-in-class monoclonal antibody from Incyte (INCY) that selectively targets mutant calreticulin (mutCALR), a driver mutation in about 25-30% of myeloproliferative neoplasms. It received FDA Breakthrough Therapy designation in December 2025 for essential thrombocythemia (ET) with Type 1 CALR mutations. Promising Phase 1 data presented at EHA 2026 showed 87% hematologic response in ET (70% complete) and meaningful spleen reductions in myelofibrosis. A Phase 3 trial in ET (EXCALIBUR-ET2) began enrolling in September 2026, but primary completion is not expected until 2029, making it a long-duration pipeline asset at a diversified, commercially-established biotech.
How It Works
INCA033989 is a laboratory-made antibody designed to recognize and bind only to a specific mutated form of a protein called calreticulin (CALR) found on the surface of certain blood-cancer cells. About 25-30% of patients with myelofibrosis or essential thrombocythemia have cancer cells carrying this CALR mutation. By latching onto the mutated protein, the antibody blocks the cancer-driving signals that cause abnormal blood-cell growth and platelet production, while leaving healthy cells untouched. It is designed to be a more targeted alternative to current treatments that broadly suppress blood-cell production.
Trial Status
Two Phase 1 trials (NCT05936359, NCT06034002) completed dose escalation and reported positive data at EHA June 2026. A registrational Phase 3 trial EXCALIBUR-ET2 (NCT07623200) versus best available therapy in CALR-mutant ET began enrollment September 8, 2026, targeting 426 patients. A Phase 3 registrational program for myelofibrosis is in planning.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 EXCALIBUR-ET2 enrollment updates and interim analyses (no dates specified, primary completion ~2029)
- Initiation of Phase 3 registrational program for myelofibrosis (planning stage, no date set)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INCYTE CORP 8-K INCY ·Originating report